Prostate Cancer Discoveries Digest
Welcome to your monthly summary of the notable research studies and developments that help provide greater insight into prostate cancer causes, treatments, outcomes, and survivorship.
Welcome to the November 2024 edition of ZERO's Prostate Cancer Discoveries Digest! The latest information on treatment, diagnostics, outcomes, and more has been pulled from the headlines and delivered to your inbox.
To make sure you receive this monthly newsletter, be sure to add ZERO Prostate Cancer to your contact list.
ZERO Prostate Cancer does not endorse any particular article or finding that may be featured.
Researchers at Johns Hopkins Medicine are seeing evidence that a healthy diet may help prevent low-grade prostate cancer from progressing to a more aggressive disease.
» Full Article from Johns Hopkins Medicine
Pesticides & Prostate Cancer Incidence and Mortality
In a study examining 295 distinct pesticides, twenty-two were associated with prostate cancer incidence, and 4 were associated with prostate cancer mortality.
» Full Article from ACS Journals
AI-Based MRI Tumor Sizing Could Improve Prostate Cancer Prognosis
Researchers in the Department of Radiation at Mass General Brigham trained an AI (artificial intelligence) model based on images of prostate cancer tumors from 732 patients. Then, they investigated whether the AI's estimates were associated with treatment success.
» Full Article from Technology Networks
Prostate Cancer Detection: Achieving an Optimal Balance
The FDA approved the PSA blood test for prostate cancer screening in 1994. However, new biomarkers and imaging modalities must be developed to reduce unnecessary biopsies without compromising the detection of clinically significant prostate cancers.
Trial Launches for Post-Prostatectomy Radiation Therapy
The first patient has been enrolled in a clinical trial assessing the safety and effectiveness of the Barrigel rectal spacer for patients who are undergoing radiation therapy after radical prostatectomy.
» Full Article at Urology Times
Black Men's Experiences of Support Following Treatment for Prostate Cancer in England
Twenty Black African and Black Caribbean men were interviewed in a qualitative study aimed at better understanding Black men's experiences of support following prostate cancer treatment. Six themes emerged: dealing with the treatment effect, support from loved ones, individuals and organizations, healthcare support, spirituality, and positivity.
FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer
The FDA has received a request to approve a new version of leuprolide mesylate, called Camcevi. This version is designed to be taken every three months for patients with advanced prostate cancer, in addition to a six-month version that was approved in May 2021.
Advanced Prostate Cancer Treatment Cost Analysis and Patient Impact in the VA Healthcare System
A video and transcript discuss a cost analysis and patient impact for advanced prostate cancer patients within the VA health system.
ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to take the place of medical professionals or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan.
Join the Prostate Cancer Discoveries Digest Email List
Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you.